EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program

Gernot Fugger, Ulrich Rabl, Lucie Bartova, Valentin Popper, Victoria Watzal, Dominik Ivkic, Jakob Donath, Constance Busvine iD, Waldemar Greil, Sermin Toto, Renate Grohmann, Richard Frey und 3 weitere

International Journal of Neuropsychopharmacology · 01.07.2026 · 29 (7)

DOI: 10.1093/ijnp/pyag029 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 07.06.2026. Verfasst von Gernot Fugger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapeutic Medicine, University Hospital St. Pölten, Karl Landsteiner Private University of Health Sciences, Krem…. Hauptthemen laut MEDLINE: Restless Legs Syndrome, Pharmacovigilance, Antipsychotic Agents, Antidepressive Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Secondary Restless Legs Syndrome (RLS) has repeatedly been associated with psychopharmacotherapy, especially antidepressants and antipsychotics. However, existing evidence is conflicting in terms of the magnitude of the association as well as the significance of substance classes or individual compounds. The objective of the present study was to evaluate secondary RLS linked to psychotropic medication in real-world, inpatient clinical routine treatment settings.

Methods

A large dataset from a multinational pharmacovigilance program in German-speaking countries (Arzneimittelsicherheit in der Psychiatrie, “Drug safety in Psychiatry”) from January 2001 to December 2016 was retrospectively analyzed.

Results

In a total of 340 099 monitored inpatients, 67 cases of newly diagnosed and severe RLS related to psychotropic drug treatment were recorded equivalent to a relative frequency of 0.02%. Over 80% of the cases were attributable to two compounds: the antidepressant mirtazapine and the antipsychotic quetiapine. Mirtazapine was found in 39 patients, while quetiapine was found in 16 patients with secondary RLS. For both substances, drug dosages were generally low at onset of secondary RLS. Most cases exhibited an onset within 1 or 2 days after dosage start or change.

Conclusion

Histamine neurotransmission may represent a crucial common denominator in terms of secondary RLS in association with psychopharmacotherapeutics, as both substances exhibit antihistamingeric effects at lower dosages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Restless Legs SyndromePharmacovigilanceAntipsychotic AgentsAntidepressive AgentsPsychotropic DrugsQuetiapine FumarateHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

Antidepressive AgentsAntipsychotic AgentsDrug-Related Side Effects and Adverse ReactionsPsychopharmacologyRestless Legs Syndrome

Substanzen

Antipsychotic AgentsAntidepressive AgentsPsychotropic DrugsQuetiapine Fumarate

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapeutic Medicine, University Hospital St. Pölten, Karl Landsteiner Private University of Health Sciences, Krems an der Donau, Austria.
  • Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
  • Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
  • Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland.
  • Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany.
  • Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Constance Busvine, Siegfried Kasper

Zitieren

APA

Fugger, G., Rabl, U., Bartova, L., Popper, V., Watzal, V., Ivkic, D., Donath, J., Busvine, C., Greil, W., Toto, S., Grohmann, R., Frey, R., Konstantinidis, A., Erfurth, A., & Kasper, S. (2026). Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program. International Journal of Neuropsychopharmacology, 29(7). https://doi.org/10.1093/ijnp/pyag029

Vancouver

Fugger G, Rabl U, Bartova L, Popper V, Watzal V, Ivkic D, et al. Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program. International Journal of Neuropsychopharmacology. 2026;29(7). doi:10.1093/ijnp/pyag029

BibTeX
@article{Fugger2026,
  author = {Fugger, Gernot and Rabl, Ulrich and Bartova, Lucie and Popper, Valentin and Watzal, Victoria and Ivkic, Dominik and Donath, Jakob and Busvine, Constance and Greil, Waldemar and Toto, Sermin and Grohmann, Renate and Frey, Richard and Konstantinidis, Anastasios and Erfurth, Andreas and Kasper, Siegfried},
  title = {Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  volume = {29},
  number = {7},
  doi = {10.1093/ijnp/pyag029}
}
Kostenlos starten →